You are here

H1 Launches ‘Strategy as a Service’ Offering That Helps Life Sciences Companies Cut Time-to-Market in Half

DaVinci service helps clients identify and unlock valuable opportunities faster

NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- H1, the first company to arm healthcare organizations with live data insights to help fight diseases, today launched a new Strategy as a Service offering designed to help clients accelerate the market research phase of drug development. The company’s new DaVinci service, which can help clients cut time-to-market in half, spans:

  • Market Landscape: Validate your strategy against an up-to-date, comprehensive picture of products and patient needs in your market.
  • Competitive Intelligence: Anticipate market shifts with an insider’s view on the competition.
  • Opportunity Identification: Zero in on the most promising targets across the unmet need, pathway, or technology by systematically evaluating the universe of potential targets.

The service is delivered jointly by H1 and partner Innovatively, a boutique life sciences consultancy based in New York City with deep expertise in healthcare business intelligence.

“It typically takes 10 years and $2.5B to bring a drug to market,” said An Nguyen, CEO of Innovatively. “Our DaVinci service is designed to help biotech and life sciences companies leverage data to quickly narrow down their list of target opportunities from thousands to the top 10, at a fraction of the cost and time it would traditionally take. With that data in hand, our clients can then hit the ground running in the most promising markets with much less risk.”

Ben Kamens, Founder and CEO at Spring Discovery, which is accelerating the discovery of therapies for aging, was one of the first companies to leverage the DaVinci service. “We’ve been working closely with An and team to build a curated database that helps us identify the right markets to target, and to understand those markets at an early stage in the process. In biotech, you have to make large and expensive choices early, and understanding the impact of those choices across dimensions - clinical, commercial, regulatory - is critical. DaVinci has played a big role helping us determine the best ways to apply our technology to start advancing therapeutics.”

There are typically 10 or more steps a life sciences or healthcare company has to take to bring a new drug to market, from coming up with a concept and obtaining grants to conducting clinical trials and analyzing the results. All of those steps have different repositories of data and it can cost millions and take years to collect and analyze all of that information.

H1’s DaVinci repurposes existing research data located in disparate sources all over the world to help healthcare companies accelerate their strategic planning and improve their strategies. It systematically evaluates therapeutic areas and identifies where a life science company may have an unfair advantage; helps expand the company’s development pipeline by identifying and evaluating potential assets to in-license; and supports new product planning with competitive intelligence.

“Clinical and scholarly data are critical assets for life sciences companies, but because it is spread out all over the world in separate databases rather than centralized, it is difficult to access,” said Ariel Katz, Chief Product Officer of H1. “H1 leverages machine learning technology to find relevant data, quickly gathering what each client needs from thousands of disparate sources, and then analyzing it for clients, to distill what’s most important and help them make better decisions more quickly.”

Pricing for the DaVinci service begins at $10,000. Learn more at

About H1
H1 is the first company to arm healthcare organizations with live data insights to help fight diseases. The company provides real-time data from across the data universe to support the end-to-end therapeutic development process from fundraising to product development to product launch, helping healthcare and life sciences companies make smarter scientific decisions. Working with medical affairs and strategy teams who span all phases of the development lifecycle, H1 provides the complete picture of institutions, experts, scholarly content, markets, competitors and new opportunities through research grounded in actual data and clinical findings.  Learn more at

Media contact:
Michelle Faulkner
+1 617-510-6998 

Thursday, September 20, 2018 - 09:00